Publications

• Johnstone TC, Park GY, Lippard SJ. Understanding and improving platinum anticancer drugs
    phenanthriplatin. Anticancer Res. 2014 Jan;34(1):471-6.
• Rosenberg B, VanCamp L, Trosko JE, Mansour VH. Platinum compounds: a new classof potent
    antitumour agents. Nature. 1969 Apr 26;222(5191):385-6.
• Dasari S, Tchounwou PB. Cisplatin in cancer therapy: molecular mechanisms ofaction. Eur J Pharmacol.
   2014 Oct 5;740:364-78.
• Ruggiero A, Trombatore G, Triarico S, Arena R, Ferrara P, Scalzone M, Pierri F & Riccardi R 2013
   Platinum compounds in children with cancer: toxicity and clinical management. Anti-Cancer Drugs 24
   1007-1019.
• Mantia-Smaldone GM, Edwards RP, Vlad AM. Targeted treatment of recurrent platinum-resistant ovarian
   cancer: current and emerging therapies. Cancer Management and Research. 2011;3:25-38.
• Adlard JW, Richman SD, Seymour MT, Quirke P. Prediction of the response of colorectal cancer to
   systemic therapy. Lancet Oncol. 2002 Feb;3(2):75-82. Review.
• Tang CH, Parham C, Shocron E, McMahon G, Patel N. Picoplatin overcomes resistance to cell toxicity in
   small-cell lung cancer cells previously treated with cisplatin and carboplatin. Cancer Chemother Pharmacol.
   2011 Jun;67(6):1389-400.
• S Tsuji, Y Midorikawa, T Takahashi, K Yagi, T Takayama, K Yoshida, Y Sugiyama, and H Aburatani.
   Potential responders to FOLFOX therapy for colorectal cancer by Random Forests analysis. British
   Journal of Cancer (2012) 106, 126-132
• Lee JK, Havaleshko DM, Cho H, Weinstein JN, Kaldjian EP, Karpovich J, Grimshaw A,and Theodorescu
   D., A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery.
   PNAS (20) 104 (32), 1386-1391.
• Wilson PM, Labonte MJ, Lenz HJ. Molecular markers in the treatment of metastatic colorectal cancer.
   Cancer J. 2010 May-Jun;16(3):262-72.
• Ferriss JS, Kim Y, Duska L, Birrer M, Levine DA, Moskaluk C, Theodorescu D, Lee JK. Multi-gene
   expression predictors of single drug responses to adjuvant chemotherapy in ovarian carcinoma:
   predicting platinum resistance. PLoS One. 2012;7(2):e30550.
• Daniel L. Gustafson, Jared S. Fowles, BS, Kristen C. Brown, and Dan Theodorescu, Drug Selection in the
   Genomic Age: Application of the Coexpression Extrapolation Principle for Drug Repositioning in Cancer
   Therapy, 2015, Drug Repurposing, Rescue, and Repositioning, v1(1), p17-21
• Tsuji S, Midorikawa Y, Takahashi T, Yagi K, Takayama T, Yoshida K, Sugiyama Y, Aburatani H. Potential
    responders to FOLFOX therapy for colorectal cancer by Random Forests analysis. Br J Cancer.
    2012 Jan 3;106(1):126-32.
• Midorikawa Y, Tsuji S, Takayama T, Aburatani H. Genomic approach towards personalized anticancer
    drug therapy. Pharmacogenomics. 2012 Jan;13(2):191-9